London — Johnson & Johnson (J&J) boosted its financial guidance for the year, a sign the health-care giant believes it can successfully navigate the strains placed on the industry by the pandemic.
But its second-quarter profit was weaker than analysts had expected. After reining in its outlook earlier this year, the company said it now expects adjusted earnings for the full year of $7.75 to $7.95 a share, and revenue of $81bn to $82.5bn...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.